Express News | Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Moomoo 24/7Apr 4 09:00 ET
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-Small Cell Lung Cancer
Yahoo FinanceApr 4 08:30 ET
Express News | Trading Halt: Halted at 8:25:00 A.m. ET - Trading Halt: Halt News Pending
Moomoo 24/7Apr 4 08:25 ET
Trading Halt: Halt Status Updated at 9:10:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:10:00 AM ET: Quotation Resumption: News and Resumption Times
BenzingaJan 12 09:10 ET
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
BenzingaJan 11 19:50 ET
EFFECTOR Therapeutics (NASDAQ:EFTRW) Shares Down 13.1%
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) traded down 13.1% on Wednesday . The company traded as low as $0.10 and last traded at $0.12. 898 shares traded hands during trading, a decline
Defense WorldApr 20, 2023 03:26 ET
EFFECTOR Therapeutics (NASDAQ:EFTRW) Trading Up 21.4%
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) shot up 21.4% on Wednesday . The stock traded as high as $0.17 and last traded at $0.16. 1,403 shares changed hands during mid-day trading, a de
Defense WorldMar 9, 2023 02:41 ET
EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Short Interest Update
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 21,500 shares, an i
Defense WorldFeb 1, 2023 02:13 ET
EFFECTOR Therapeutics (NASDAQ:EFTRW) Trading Down 15.7%
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) traded down 15.7% during mid-day trading on Thursday . The stock traded as low as $0.10 and last traded at $0.16. 3,151 shares were traded dur
Financial News LiveJan 28, 2023 09:31 ET
Short Interest in EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Decreases By 23.9%
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 26,800 shares
kopsourceJan 2, 2023 21:51 ET
EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Sees Significant Decline in Short Interest
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 26,800 share
Financial News LiveJan 1, 2023 22:31 ET
No Data
No Data